OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialRecruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

A phase 1/2 trial of CTX112 in hodgkin lymphoma and non-hodgkin lymphoma, run by CRISPR Therapeutics AG, now recruiting.